Why Use DEFINITY®? Product Support
Product Support
From product training and promotional programs, to experienced Medical Liasons and sales representatives, DEFINITY® is backed by world-class service and support.
Product Support Programs
-
On-site product training by dedicated DEFINITY® Medical Liaisons
-
Over 1,600 institutions have received DEFINITY® promotional programs
-
Highly trained sales and clinical support personnel.
-
Assistance with product-related reimbursement questions regarding DEFINITY®
(1-800-362-2668 x7995)
Lantheus Medical Imaging cannot guarantee coverage or payment for products or procedures. Payer policies can widely vary and third party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. For more specific information, contact your third-party payer directly in order to obtain up-to-date coverage, coding and payment information.
Medical Information to answer medical and technical questions about DEFINITY® (800–343–7851)
Click here for more contact information.
Industry Links
Please note that by clicking on the links below, you will be leaving DEFINITYImaging.com. Lantheus Medical Imaging has no connection with and takes no responsibility for the content of these sites.
American College of Cardiology (ACC)
American Heart Association (AHE)
American Society of Echocardiography (ASE)
American Society of Echocardiography- Contrast Zone (ASE)
American
Institute of Ultrasound in Medicine (AIUM)
American
Registry of Diagnostic Medical Sonographers (ARDMS)
Radiological
Society of North America (RSNA)
Society
of Diagnostic Medical Sonography (SDMS)
Society
of Radiologists in Ultrasound (SRU)
INDICATIONS
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
CONTRAINDICATIONS
Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.
IMPORTANT SAFETY INFORMATION
WARNING: Serious Cardiopulmonary Reactions Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [See WARNINGS AND PRECAUTIONS (5.1)]. Most serious reactions occur within 30 minutes of administration.
|
In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration [See ADVERSE REACTIONS (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions [See Postmarketing Experience (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.
Please see full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.
